Method for Preparing a Recombinant PDRN Library, Screened Polynucleotides, and Compositions Comprising the Same
By fragmenting and recombinantly constructing PDRN libraries, the method addresses the limitations of traditional PDRN production, facilitating scalable and effective skin regeneration and cell proliferation applications.
Patent Information
- Application Number
- KR1020260025408
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2025-02-18
- Filing Date
- 2026-02-09
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-02-09
AI Technical Summary
The production of polydeoxyribonucleotide (PDRN) from salmonid fish is labor-intensive and economically challenging due to the limited availability of fish sources, hindering mass production and scalability.
A method is developed to construct a recombinant PDRN library by fragmenting PDRN from fish testes, inserting it into a vector, and introducing it into a host cell, followed by screening for clones with specific cell proliferation and skin regeneration activities.
This approach allows for the systematic diversification and selection of highly active recombinant PDRN candidates, enabling stable production and application in skin regeneration and cell proliferation promotion.
Smart Images

Figure 112026016675300-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to polydeoxyribonucleotide (PDRN), and more specifically to a method for preparing a recombinant PDRN library by segmenting fish testis-derived PDRN, inserting it into a vector, and introducing it into a host cell, a polynucleotide selected from said library, and a recombinant vector / host cell and a composition comprising said polynucleotide. Background Technology
[0002] Polydeoxyribonucleotide (PDRN) is DNA extracted from the sperm and testes of salmonid fish and consists of large and small fragments. It is used worldwide as a tissue regeneration treatment and cosmetic agent due to its excellent ability to enhance cell proliferation and its almost non-existent side effects. In the past, it was used for purposes such as skin whitening, firming, and moisturizing. Recently, however, it has been recognized as a skin-improving cosmetic with various functions, including treating acne scars, accident scars, stretch marks, fine lines, melasma, and blemishes. It is sold by pharmaceutical and cosmetic companies and is also being used as a procedure in hospitals.
[0003] Regenerative medicine is rapidly emerging as a new paradigm for disease treatment within the healthcare industry. The regenerative medicine market is reported to have shown growth in recent years, and the domestic cosmetics market is also known to be maintaining this growth trend. The PDRN field falls under the regenerative medicine market.
[0004] PDRN, with proven safety and efficacy, possesses tissue regenerative properties. By stimulating A2 receptors, which are skin regeneration signaling pathways, it promotes the secretion of various growth factors, facilitates the formation of capillaries via Vascular Endothelial Growth Factor (VEGF), improves blood circulation, exerts anti-inflammatory effects, and prevents capillary leakage. PDRN acts in conjunction with DNA metabolic pathways present in human cells to stimulate the regeneration and metabolic activity of fibroblasts, thereby helping to maintain optimal physical condition.
[0005] Furthermore, PDRN is believed to complement the effects of various skin stem cells when used together, as it regenerates and promotes the growth of fibroblasts—a type of skin stem cell—and generates elastic fibers such as collagen and elastin to rapidly regenerate damaged skin, while also improving blood circulation to maintain skin elasticity. It is already used as an injectable pharmaceutical and acts to help maintain optimal skin condition by physiologically stimulating the regenerative and metabolic activity of fibroblasts, which are constantly present in human cells.
[0006] However, obtaining PDRN requires time and labor to farm or collect salmonid fish. Furthermore, there are economic difficulties in mass production due to the limitation that it can only be obtained from a limited number of fish. The problem to be solved
[0007] Accordingly, to solve the aforementioned problems, the present invention aims to construct a PDRN library by obtaining multiple clones containing different inserts through a genetic recombination (cloning) method in which PDRN obtained from fish testes is fragmented, inserted into a vector, and introduced into a host cell.
[0008] Accordingly, the present invention aims to provide a method for preparing a recombinant PDRN (Polydeoxyribonucleotide) library, a PDRN library constructed by said method, a recombinant PDRN fragment selected from said library, a recombinant vector, a recombinant host cell, and a composition comprising the same. means of solving the problem
[0009] The present invention provides a method for preparing a recombinant PDRN (Polydeoxyribonucleotide) library comprising the following steps:
[0010] (a) A step of extracting and purifying PDRN from fish testes;
[0011] (b) a step of preparing PDRN fragments by segmenting the extracted PDRN by physical shearing;
[0012] (c) a step of constructing a recombinant vector library by inserting the above-mentioned segmented PDRN fragments into a vector;
[0013] (d) a step of introducing the above recombinant vector library into a host cell to produce a recombinant host cell library; and
[0014] (e) a step of isolating individual clones from the recombinant host cell library and screening candidate clones based on at least one of cell proliferation-promoting activity and skin regeneration-related activity, targeting the inserts of the individual clones or the recombinant PDRN obtained from the individual clones.
[0015] In addition, the present invention provides a PDRN library comprising a plurality of recombinant vectors, wherein each of the plurality of recombinant vectors has a PDRN fragment inserted therein that is obtained by segmenting PDRN derived from fish testes.
[0016] In addition, the present invention provides a PDRN library comprising a plurality of recombinant host cells, wherein each of the plurality of recombinant host cells comprises one of the aforementioned recombinant vectors.
[0017] In addition, the present invention provides an isolated polynucleotide comprising the base sequence of SEQ ID NO. 2 or SEQ ID NO. 3.
[0018] In addition, the present invention provides a polynucleotide comprising a complementary sequence of the aforementioned polynucleotide.
[0019] In addition, the present invention provides a recombinant vector comprising the aforementioned polynucleotide.
[0020] In addition, the present invention provides a recombinant host cell into which the aforementioned recombinant vector has been introduced.
[0021] In addition, the present invention provides a method for producing recombinant PDRN, comprising the steps of culturing the aforementioned recombinant host cell and recovering the aforementioned polynucleotide from the culture.
[0022] In addition, the present invention provides a skin regeneration composition comprising the aforementioned polynucleotide as an active ingredient. Effects of the invention
[0023] According to the present invention, by fragmenting a natural PDRN mixture and converting it into a recombinant library, diversity in sequence and length can be systematically secured, and highly active candidates can be selected through function-based screening. Furthermore, based on the sequence information of the selected candidates, recombinant PDRN can be stably produced and secured, and can be applied as a composition for skin regeneration or cell proliferation promotion. Brief explanation of the drawing
[0024] Figure 1 is a diagram showing the results of confirming the segmentation pattern of fish testis-derived PDRN by electrophoresis according to sonication treatment times (3 hours, 5 hours, 7 hours, 10 hours, and 14 hours). Figure 2 is a diagram showing the results of confirming the insert (recombinant PDRN fragment) by amplifying it through PCR after purifying the plasmid from the recombinant vector. Figure 3 is a diagram showing the results of comparing the cell proliferation effects of multiple recombinant PDRN candidates (#1 to #100) in WST-based cell proliferation screening using HaCaT cells. Figure 4 is a diagram showing the results of comparing the cell proliferation effects of multiple recombinant PDRN candidates (#1 to #100) in WST-based cell proliferation screening using HaCaT cells. Figure 5 is a diagram showing the results of comparing and quantifying the wound closure rate over time between the natural PDRN treatment group and the recombinant PDRN candidate (#1 and #7) treatment group in a HaCaT cell-based wound healing assay. Figure 6 is a diagram showing that high homology with the ISCUb mRNA sequence derived from Coregonus maraena was confirmed as a result of performing BLAST analysis on the insert sequence of recombinant PDRN candidate (#1). Figure 7 is a diagram showing that high homology with the ISCUb mRNA sequence derived from Coregonus maraena was confirmed as a result of performing BLAST analysis on the insert sequence of the recombinant PDRN candidate (#7). Specific details for implementing the invention
[0025] Unless specifically defined otherwise, terms used in this specification have the meanings commonly understood in the art.
[0026] In this specification, "PDRN" refers to a set of polynucleotides derived from fish testes and may include naturally derived PDRN and polynucleotides derived from said naturally derived PDRN (segmented, cloned, amplified, etc.).
[0027] In this specification, "fish testis" refers to fish gonad tissue as a raw tissue for obtaining PDRN. The type, breed, origin, time of harvest, and storage form (such as whether it is frozen) of the fish testis do not limit the scope of the invention and include all fish testis commonly used in the art.
[0028] In this specification, "PDRN fragment" refers to a nucleic acid fragment obtained by cleaving PDRN.
[0029] In this specification, "maximum length in the length distribution of PDRN fragments" refers to a size corresponding to the upper limit of a PDRN fragment signal (band or smear) observed in electrophoresis (including agarose gel electrophoresis) or equivalent size analysis, and can be calculated by comparison with a nucleic acid size standard.
[0030] In this specification, “length distribution upper value (L95)” refers to the size corresponding to the 95 percent point of the cumulative distribution based on the total nucleic acid signal (total amount) when the results of electrophoresis or equivalent size analysis are quantified by image analysis or equivalent quantification methods. Calculation of L95 is optional and may be performed as necessary to verify the reproducibility of fragmentation conditions.
[0031] In this specification, "PDRN library" means a set of multiple recombinant vectors into which PDRN-derived fragments having different lengths and / or different nucleotide sequences are respectively inserted, or a set of multiple transgenic host cells (colonies) each containing said recombinant vectors.
[0032] The present invention aims to provide a technology for constructing a recombinant PDRN library capable of reproducibly obtaining, amplifying, and selecting PDRN in a laboratory environment by fragmenting naturally derived PDRN, inserting it into a vector, and introducing it into a host cell to secure multiple clones containing different inserts. Specifically, the present invention aims to provide a method for preparing a recombinant PDRN (Polydeoxyribonucleotide) library, a PDRN library constructed by said method, and a recombinant PDRN fragment selected from said library, a recombinant vector, a recombinant host cell, and a composition.
[0033] A method for manufacturing a PDRN library according to one embodiment of the present invention may include, for example, the following steps.
[0034] (a) Step of extracting and purifying PDRN from fish testes
[0035] (b) A step of preparing PDRN fragments by segmenting the extracted PDRN by physical shearing.
[0036] (c) A step of constructing a recombinant vector library by inserting the above-mentioned segmented PDRN fragments into a vector.
[0037] (d) a step of introducing the above recombinant vector library into a host cell to produce a recombinant host cell library
[0038] (e) isolating individual clones from the recombinant host cell library and selecting candidate clones by screening the inserts of the individual clones or the recombinant PDRN obtained from the individual clones using at least one of cell proliferation-promoting activity and skin regeneration-related activity as an indicator.
[0039] The present invention will be explained step by step below.
[0040] (a) PDRN extraction and purification step
[0041] Step (a) above may be a step of extracting PDRN from fish testes and purifying the PDRN by removing proteins, lipids, salts, and other impurities. The extraction and purification may be performed by various methods known in the art, as long as PDRN having a desired molecular weight distribution and purity can be obtained.
[0042] In one embodiment, the extraction and purification may include hot water extraction. In one embodiment, the purification may include the step of recovering the supernatant by centrifugation. In one embodiment, the purification may include treatment with a surfactant and a proteolytic enzyme, removal of impurities under basic conditions, and recovery by alcohol precipitation. The recovered PDRN may be solidified through a drying process as needed.
[0043] Fish testes are DNA-rich tissues, and in the present invention, PDRN can be obtained using fish testes as a raw material. In one embodiment, the fish may be a salmonid fish.
[0044] (b) PDRN segmentation step
[0045] Step (b) above may be a step of preparing PDRN fragments by cleaving the extracted PDRN by physical shearing. In this specification, "physical shearing" is a concept distinct from chemical or enzymatic cleavage and refers to the process in which nucleic acids are cleaved by an external force.
[0046] Physical shearing may include at least one of mechanical shearing methods known in the art, such as ultrasonic crushing, high-shear mixing, fluid shearing, micropore passage, and spray shearing. In one embodiment, physical shearing may be performed by ultrasonic crushing.
[0047] The length distribution of fragmented PDRN fragments can be verified through electrophoresis or equivalent size analysis. In this case, the "maximum length in the PDRN fragment length distribution" refers to the size corresponding to the upper boundary of the PDRN fragment signal observed in the analysis. Calculation of L95 is optional and may be performed as needed to verify the reproducibility of fragmentation conditions.
[0048] In one embodiment, the maximum length in the length distribution of the segmented PDRN fragment can be adjusted to be 700 bp or less, and in another embodiment, the maximum length can be adjusted to be 200 bp or less. In one embodiment, the length of the segmented PDRN fragment may be in the range of 100 bp or more and 700 bp or less, 200 bp or more and 600 bp or less, 200 bp or more and 500 bp or less, 100 bp or more and 400 bp or less, 100 bp or more and 300 bp or less, 200 bp or more and 300 bp or less, or 100 bp or more and 200 bp or less.
[0049] In one embodiment, the ultrasonic fragmentation is performed under conditions of an amplitude of 20 or more and 40 or less and an duration of 10 or more and 15 or less, so that the maximum length in the length distribution of the fragmented PDRN fragments is 200 bp or less. Whether the length is "200 bp or less" can be determined based on whether the upper boundary of the fragment signal in the electrophoresis result is located at 200 bp or less, and the ultrasonic conditions (amplitude, time, pulse setting, buffer composition, etc.) can be adjusted as needed.
[0050] Controlling fragment length in this way can reduce insert length variation during subsequent A-tailing and TA cloning processes, thereby contributing to improved reproducibility in library construction. Additionally, relatively short polynucleotide fragments can be advantageous for processing, introduction, and intracellular action in cell-based evaluations, thus providing a library suitable for candidate clone selection.
[0051] (c) Steps to build the recombination vector library
[0052] Step (c) above may be a step of constructing a recombinant vector library by inserting the segmented PDRN fragments into a vector. The vector may include a cloning vector and, if necessary, may include a selection marker and a replication origin.
[0053] Here, "vector" refers to a nucleic acid molecule configured to allow the insertion of a PDRN fragment and to be maintained or amplified within a host cell, and "recombinant vector" refers to a vector into which the PDRN fragment is inserted. Additionally, "insert" refers to the PDRN fragment inserted into the recombinant vector.
[0054] In one embodiment, the fragmented PDRN fragment can be inserted into a vector via TA cloning after undergoing end repair and 3' end adenylation treatment. In another embodiment, the fragmented PDRN fragment can be inserted into a vector via smooth end cloning. The insertion reaction can be performed using a ligase and a buffer, and the reaction conditions can be set according to the vector type and insertion conditions.
[0055] (d) Host cell library preparation step
[0056] Step (d) above may be a step of introducing a recombinant vector library into a host cell to produce a recombinant host cell library. The host cell may include, for example, Escherichia coli, but the present invention is not limited to a specific host cell. For example, it may include E. coli DH5α, E. coli JM109, E. coli BL21(DE3), E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E. coli W3110, etc.
[0057] The introduction method may include methods commonly used in the industry, such as heat shock or electroporation. After introduction, the host cells may be cultured in a selective medium to form individual colonies. In one embodiment, blue-white screening may be used for the primary screening of colonies containing the insert, or the presence of the insert may be confirmed by colony PCR.
[0058] (e) Screening and candidate clone selection step
[0059] The above step (e) may be a step of isolating individual clones from a recombinant host cell library and selecting candidate clones by screening the inserts of individual clones or recombinant PDRN obtained from individual clones using at least one of cell proliferation-promoting activity and skin regeneration-related activity as an indicator.
[0060] Here, "recombinant PDRN obtained from individual clones" can be obtained by purifying the plasmid and then amplifying the insert by PCR, or by cleaving the plasmid with a restriction enzyme to recover the insert.
[0061] Screening may include (i) verification of the inclusion of the insert, (ii) verification of the insert sequence, and (iii) evaluation of function-based activity. (i) Verification of the inclusion of the insert may include blue-white screening or colony PCR, etc. (ii) Sequence verification may include analyzing the nucleotide sequence of the insert after plasmid purification. (iii) Evaluation of function-based activity may be performed using indicators at the cellular level.
[0062] In one embodiment, skin regeneration-related activity may include an evaluation of wound healing activity, and cell proliferation-promoting activity may be evaluated by a WST-based cell proliferation assay. The criteria for activity evaluation may be set by selecting candidate clones that show a significant increase compared to a negative control (PBS, etc.) while simultaneously exhibiting activity equivalent to or greater than that of a positive control, the naturally derived PDRN-treated group. In one embodiment, 'equivalent level' may be defined as an activity level of 90 percent or more compared to the naturally derived PDRN-treated group.
[0063] In the present invention, "Sequence No. 1" is a specific core segment (overlapping sequence) commonly identified during the candidate clone selection process, and in one embodiment, Sequence No. 1 may be defined as a continuous sequence including CCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCG.
[0064] In the present invention, "Sequence No. 2" and "Sequence No. 3" each refer to the full-length sequences of inserts identified in different candidate clones selected in the examples. That is, Sequence No. 2 and Sequence No. 3 correspond to the entire nucleotide sequences of PDRN fragments inserted into a recombinant vector. Sequence No. 2 or Sequence No. 3 may include the sequence of Sequence No. 1 as a continuous sequence.
[0065] In this specification, "isolated polynucleotide" means nucleic acid isolated from a state existing in a tissue or cell in its natural state and substantially isolated from other cellular components or impurities. The isolated polynucleotide may include insert DNA recovered from a recombinant vector, or DNA obtained by amplifying an insert using a template.
[0066] The present invention provides an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO. 2 or SEQ ID NO. 3. Here, "comprising" may include not only the case where the entire full-length sequence of SEQ ID NO. 2 or 3 is included, but also a modification that includes a portion of the entire full-length sequence of SEQ ID NO. 2 or 3 while maintaining functional characteristics.
[0067] The present invention also provides a polynucleotide consisting of the base sequence of SEQ ID NO. 2 or SEQ ID NO. 3.
[0068] The present invention may also include a polynucleotide having 95 percent or more sequence identity with respect to the entire length of SEQ ID NO. 2 or SEQ ID NO. 3. Sequence identity may be calculated using an alignment algorithm known in the art and, unless specifically stated otherwise, may be calculated based on the entire length of a reference sequence (SEQ ID NO. 2 or 3).
[0069] A range of 95 percent or more of sequence identity is intended to include the core region of SEQ ID NO. 1 that is commonly identified in candidate clones, while covering limited base substitutions, insertions, or deletions that may occur during the library construction, amplification, and replication processes. In one embodiment, the modified polynucleotide of the said range may include SEQ ID NO. 1 as a continuous sequence and may be permitted within a range in which the functional characteristics of the said core region are substantially maintained.
[0070] In one embodiment, the polynucleotide may have a total length of 50 bp or more and 700 bp or less.
[0071] The present invention may also include a polynucleotide consisting of a complementary sequence of the polynucleotide.
[0072] The present invention provides a recombinant vector comprising the polynucleotide described above. The recombinant vector refers to a vector into which the polynucleotide is inserted and may include a cloning vector. The recombinant vector may include a selection marker and a replication origin and may be maintained or amplified within a host cell.
[0073] The present invention also provides a recombinant host cell into which the recombinant vector is introduced. In one embodiment, the host cell may include Escherichia coli, and the introduction method may include heat shock or electroporation, etc.
[0074] The present invention provides a method for producing recombinant PDRN, comprising the steps of culturing recombinant host cells and recovering the polynucleotide described above from said culture. Here, "recovery" refers to the process of isolating and securing a target polynucleotide from the recombinant host cells or culture.
[0075] In one embodiment, the above recovery may include one or more of the following.
[0076] (1) A method of obtaining an insert by amplifying it with PCR after purifying the plasmid.
[0077] (2) A method of obtaining an insert by cutting a plasmid with a restriction enzyme, recovering the insert, and purifying it.
[0078] The present invention provides a composition for skin regeneration comprising the aforementioned polynucleotide as an active ingredient. Here, the "active ingredient" is a component that contributes to skin regeneration-related activity, and in the present invention, the aforementioned polynucleotide may be applicable.
[0079] In one embodiment, the active ingredient may be a polynucleotide comprising or consisting of the nucleotide sequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, or a polynucleotide having 95% or more sequence identity with respect to the entire length of SEQ ID NO. 2 or SEQ ID NO. 3. In this case, the polynucleotide having 95% or more sequence identity may include a continuous sequence of SEQ ID NO. 1 and may include substitutions, insertions, or deletions within a range in which functional characteristics are substantially maintained. In another embodiment, the active ingredient may be in the form of a mixture comprising two or more of the polynucleotides.
[0080] In this specification, "skin regeneration-related activity" is a concept that includes indicators related to the improvement of skin regeneration, and in one embodiment, may include wound healing activity.
[0081] The composition may be a cosmetic composition, a quasi-drug composition, or a pharmaceutical composition. In one embodiment, the cosmetic or quasi-drug composition may be a lotion, cream, gel, essence, ampoule, patch, or mask formulation. The pharmaceutical composition may include an acceptable carrier and / or excipient and may be any one of an ointment, cream, gel, solution, suspension, or spray formulation.
[0082] The present invention will be described in more detail below through examples. These examples are intended solely to explain the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these examples according to the gist of the invention.
[0083] Examples
[0084] Example 1
[0085] PDRN extraction
[0086] A brine solution was prepared by dissolving sodium chloride (NaCl) at 8 to 12% (preferably 10%) relative to the specific gravity of purified water in 40 to 60 L (preferably 50 L) of purified water, and 10 kg of frozen salmon testes were placed in the brine solution and heated for about 1 hour to obtain a hot water extract.
[0087] After that, the hot water extract was refrigerated for about 24 hours, and the supernatant was recovered by centrifuging using a centrifuge at 4°C and 10,000 to 15,000 rpm (preferably 13,000 rpm) for about 15 minutes.
[0088] Sodium dodecyl sulfate (SDS), a proteolytic enzyme (Alcalase, Neutrase, or Protamex), and sodium hydroxide (NaOH) were added to the recovered supernatant in amounts of 10% to 12%, 0.4% to 0.6%, and 0.2% to 0.3%, respectively, and stirred at room temperature for about 24 hours. Afterward, centrifugation was repeated twice under the same conditions as above to remove the precipitate and separate the supernatant.
[0089] Next, 2M sodium hydroxide was added to the supernatant to adjust the pH to 12 to 14 (preferably 13.00), and the mixture was stirred at 4°C for 4 hours to remove impurities such as proteins. After that, isopropyl ethanol and ethyl ethanol were mixed in a ratio of about 3:7 (mixed ethanol) and refrigerated, and twice the amount of mixed ethanol relative to the supernatant was added and left at room temperature for 24 hours.
[0090] Subsequently, the mixture was centrifuged for about 15 minutes at 4°C and 10,000 to 15,000 rpm (preferably 13,000 rpm) to remove ethanol and the supernatant, and precipitated high-purity PDRN was obtained. Ethyl ethanol was added again to the PDRN and centrifuged under the same conditions as above to obtain precipitated PDRN again. Afterward, the PDRN was freeze-dried for about 72 hours.
[0091] PDRN segmentation and quantitative evaluation via ultrasonic fragmentation
[0092] To fragment PDRN, sonication was performed. The sonication machine was set to an amplitude of 30 and sonicated for 14 hours, and electrophoresis (2% agarose gel, 200V, 30 min) was performed to confirm whether the PDRN DNA was fragmented to 200 bp or less. In this example, the maximum length (upper limit) was determined based on the upper boundary of the fragment signal on the electrophoresis, and quantification of the length distribution (e.g., L95 calculation) was not performed.
[0093] In addition, to verify changes according to segmentation time, the experiment was performed for 3, 5, 7, 10, and 14 hours under an amplitude of 30, and the electrophoresis conditions were The system was set to 2% agarose gel, 0.5X TBE buffer, 200V, 30 min, and DNA size marker: 25 / 100bp DNA Ladder (Bioneer). As a result, as shown in Figure 1, it was confirmed that the length of the PDRN DNA fragment (or PDRN fragment) was reduced to 200 bp or less after 14 hours of treatment.
[0094] PDRN A-tailing
[0095] PDRN fragments of approximately 200 bp obtained through sonication were subjected to A-tailing. The reaction composition and conditions are as shown in Table 1.
[0096] Reagents volume (ul) Condition DNA 7.5 72℃, 30 min dATP 1 G.Taq buffer 1 G.Taq 0.5 DW - Total 10
[0097] PCR purification process
[0098] After the A-tailing reaction, 5 volumes of Buffer PB were mixed with 1 volume of sample and loaded onto the spin column. After centrifugation for 1 minute, the effluent was removed, washed with 750 µL of Buffer NW, and centrifuged at maximum speed for 1 minute. Subsequently, the spin column was transferred to a new tube, 50 µL of dH2O was added to the center of the membrane, left for 1 minute, and then centrifuged for 1 minute to elute the DNA. The concentration of the eluted DNA was measured using a NanoDrop UV-Vis spectrophotometer.
[0099] TA Cloning
[0100] The A-tailed PDRN fragment was TA cloned into the pGEM-T-easy vector. The composition and conditions of the ligation reaction are as shown in Table 2.
[0101] Reagents volume (ul) Condition 2X Rapid Ligation Buffer, T4 DNA Ligase 5 4℃, overnight pGEM-T-easyvector(50ng) 1 DNA fragments 3 T4 DNA Ligase (3 Weiss units / μl) 1 DW - Total 10
[0102] Transgenic
[0103] LB / ampicillin / IPTG / X-Gal plates were prepared. TOP10 competent cells were thawed on ice for about 5 minutes, then 50 sL of competent cells were mixed with 10 sL of each ligation reactant and reacted on ice for 30 minutes. Subsequently, heat shock treatment was performed at 42°C for 60 seconds, followed immediately by cooling on ice for 2 minutes.
[0104] 950 sL of SOC medium was added and incubated with shaking at 37°C and 200 rpm for 1 hour. 100 sL of each transformation culture was applied to the plates and incubated overnight at 37°C, after which white colonies were selected (blue-white selection).
[0105] Confirmation of PDRN within the strain
[0106] Plasmid DNA purification was performed on selected colonies, and PCR was performed using the purified plasmid as a template to confirm the presence of the insert (Fig. 2).
[0107] Example 2: Confirmation of skin regeneration-related effects of recombinant PDRN (Wound healing assay)
[0108] Screening of recombinant PDRN
[0109] WST-based cell proliferation screening was performed to verify whether recombinant PDRN exhibits the same level of skin cell proliferation effect as conventional PDRN. WST analysis utilizes the principle that mitochondria in living cells (primarily dehydrogenase enzymes) reduce tetrazolium salt (WST) to produce water-soluble formazan, and the absorbance of the generated formazan is proportional to the number of surviving or proliferating cells. Therefore, the cell proliferation effect of the treatment groups can be quantitatively compared through the measurement of WST absorbance.
[0110] First, recombinant PDRN was obtained via PCR following plasmid DNA purification, and screening was performed on a total of 100 obtained recombinant PDRNs (#1-100). HaCaT cells were used, and 1 x 10⁶ cells were placed in a 96-well plate. 4 After seeding, the samples were stabilized. Subsequently, the experimental groups were established as PBS-treated or recombinant PDRN-treated groups, PDRN-treated groups (PDRN group; positive control), and 100 recombinant PDRN samples. After treatment, WST reagent was added to allow the reaction to proceed, and then absorbance was measured using a microplate reader (typically at 450 nm) to compare the relative degree of cell proliferation with the control group (Figs. 3 and 4).
[0111] As a result, a tendency for increased HaCaT cell proliferation was observed in 9 treatment groups out of a total of 100 recombinant PDRNs, and among them, recombinant PDRN #1 and #7 were selected as top candidates.
[0112] Skin regeneration related effects: Wound healing assay
[0113] A wound healing assay was performed to confirm the skin regeneration (cell migration and wound healing) effects of recombinant PDRNs 1 and 7, which showed the most proliferative effects selected through the WST cell proliferation assay. Specifically, cultured HaCaT cells were seeded into a 6-well plate to a confluent state, and then a physical wound was induced by scraping the bottom of the plate with a sterile tip to simulate an environment in which skin cells are damaged. Afterward, suspended cells and debris were removed by washing with PBS, the medium was replaced, and the samples were processed.
[0114] The experimental groups were established as the natural-derived PDRN treatment group (PDRN group; positive control), the recombinant PDRN #1 treatment group, and the recombinant PDRN #7 treatment group. Each sample was treated to a final concentration of 200 ng / mL (200 ng per mL) in the medium. As shown in Figure 5, the wound site was photographed under a microscope 24 hours after wound induction, with the wound induction time set to 0 hours, and the skin regeneration effect was compared by quantitatively analyzing the wound closure rate over time (PDRN group 26.4%, recombinant PDRN #1 22.8%, recombinant PDRN #7 24.7%).
[0115] As a result, wound healing progressed after 24 hours in the recombinant PDRN #1 and #7 treatment groups, and a tendency for cell migration rate (or wound closure rate) to increase was confirmed. In addition, recombinant PDRN #1 and #7 exhibited a wound closure rate within a close range compared to the positive control (PDRN), confirming their potential as candidates for skin regeneration efficacy in a HaCaT-based in vitro wound healing model.
[0116] Example 3: Insert sequence analysis and identification of common overlapping sequences
[0117] Obtaining full insert sequence and DNA sequencing analysis
[0118] After isolating and purifying the plasmids of recombinant PDRN #1 and #7 clones, the full nucleotide sequences of the inserts of each clone were obtained by performing Sanger sequencing using a universal primer (M13F) that binds to the pGEM-T-easy vector.
[0119] The obtained nucleotide sequences were confirmed as final sequences by performing base calling and sequence purification based on the chromatogram (raw data), and as a result, the insertion length of clone #1 was confirmed to be 718 bp and the insertion length of clone #7 was confirmed to be 60 bp (see Table 3 for each sequence).
[0120] As a result of performing BLAST analysis on the obtained insert sequences, alignments showing a high degree of agreement with the ISCUb (iron-sulfur cluster scaffold protein b) mRNA sequence derived from Coregonus maraena (salmonidae, trout / salmon lineage) were confirmed in both clones #1 and #7 (E-values 2e-20 and 9e-17) (Figs. 6 and 7). Therefore, it was confirmed that the recombinant DNA contains sequences that can be interpreted as originating from the salmonidae (trout / salmon related) and includes regions with strong homology to the corresponding lineage sequences.
[0121] In addition, by comparing the insert sequences of clones #1 and #7 and analyzing the overlapping (overlapping) region, a sequence common to both inserts was identified and defined as sequence number 1.
[0122] Sequence No. 1: CCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCG
[0123] Meanwhile, the full length sequence of the insert of clone #1 can be defined as sequence number 2 and the full length sequence of the insert of clone #7 can be defined as sequence number 3 and listed in the sequence list. Sequence number 1 is a common segment included in sequence number 2 and sequence number 3, and corresponds to a core segment (overlapping sequence) that is commonly identified among the candidate clones.
[0124] division Sequence (5'→3') Common overlapping sequence (sequence number 1) CCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCG Clone #1 insert full length sequence; 718 bp (sequence number 2) TTGCTCTATAGGGCGATTGGGCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCGATTCTACCTAGTCATAAACCACATACATGTTGTTGTAACTGCGTTAGCTACCTAGTCATCAACCACATACATGTTGTTGTAACTGCGTTAGCTACCTCGTCATCAACCACATACATGTTGTTGTAACTGCGTTAGCTACCTGTCATCAACCACATACATGTTGTTGTAACTGCCTTAGCTACCTAGTCATCAACCACATACTTGTTGTTGTAACTGCGTTAGCTACCTTGGCATCAACCACATACGTGTTGTTGTAACTGCGTTAGCTACCTGGTCATCAACCACATACATGTTGGTGTAACTGCGTTAGCTAACTCCTCATCAACCAAATACATGTTGTTGAAACTGCGTTAGCTACCTTGTCATCACCACATACTTGTTGTTGTAAACTGCGTTAGCTACATTGTCATCAACCACATACATGTTGTTGAAACTGCGTAGCTACATTGTCATCAACCACATACTTGTTGGTCTGAAAATGAAGAAAATAAATGTATTGTACACATACGGTTGAGCAATAAGCTGAGTAGGCTCCGTCAGCGTATGCATACTTGTCATACAGATGACTGTCACCGTGAGAAGAATGTCCATGGATGTCCAGGCGGGGGGACGGAGACGAAGCACTAGCCTGGCTCTGGAGAAAAGTTCAGGT 클론 #7 삽입체 전장 서열; 60 bp(서열번호 3) CTACCTCTATAGGGCGATTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCG
Claims
Claim 1 A method for preparing a recombinant PDRN (Polydeoxyribonucleotide) library comprising the following steps: (a) extracting and purifying PDRN from fish testes; (b) preparing PDRN fragments by segmenting the extracted PDRN by physical shearing; (c) constructing a recombinant vector library by inserting the segmented PDRN fragments into a vector; (d) preparing a recombinant host cell library by introducing the recombinant vector library into a host cell; and (e) isolating individual clones from the recombinant host cell library and selecting candidate clones by screening the inserts of the individual clones or the recombinant PDRN obtained from the individual clones using at least one of cell proliferation-promoting activity and skin regeneration-related activity as an indicator, wherein the cell proliferation-promoting activity is evaluated by a WST-based cell proliferation assay or the skin regeneration-related activity is evaluated by a wound healing assay. Claim 2 A manufacturing method according to claim 1, wherein the maximum length in the length distribution of the segmented PDRN fragment in step (b) is 700 bp or less. Claim 3 A manufacturing method according to claim 1 or 2, wherein the physical shearing of step (b) is performed by ultrasonic crushing. Claim 4 A manufacturing method according to claim 3, wherein the ultrasonic fragmentation is performed under conditions of an amplitude of 20 or more and 40 or less and an duration of 10 or more and 15 or less, such that the maximum length in the length distribution of the segmented PDRN fragments is 200 bp or less. Claim 5 A manufacturing method according to claim 1 or 2, wherein step (b) further comprises the step of confirming the length distribution of PDRN fragments segmented by electrophoresis. Claim 6 A manufacturing method according to claim 1, wherein step (e) includes the step of identifying colonies containing an insert by blue-white screening or colony PCR. Claim 7 A manufacturing method according to claim 1, wherein step (e) comprises the step of analyzing the base sequence of an insert after purifying the plasmid. Claim 8 delete Claim 9 delete Claim 10 A method of preparation according to claim 1, wherein the recombinant PDRN obtained from the individual clone is obtained by purifying the plasmid and then amplifying the insert by PCR, or by cutting the plasmid with a restriction enzyme and recovering the insert. Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 delete Claim 17 delete Claim 18 delete Claim 19 delete Claim 20 delete Claim 21 delete Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 delete Claim 26 delete Claim 27 delete Claim 28 delete
Citation Information
Patent Citations
High throughput screening for sequences of interest
US20030077620A1
Method for high throughput screening of an environmental library
US6806048B2
Indirect fluctuation screening
WO2003050501A2
Preparation method and use of fixed-length recombinant polynucleotide / polydeoxyribonucleotide
CN113913420A
